Stockreport

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study [Yahoo! Finance]

Imunon, Inc.  (IMNN) 
PDF Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMN [Read more]